homoharringtonine;
chronic myelogenous leukaemia;
long term efficacy;
CHRONIC MYELOID-LEUKEMIA;
INTERFERON-ALPHA;
IMATINIB;
RESPONSES;
RECOMMENDATIONS;
CYTARABINE;
I/II;
D O I:
10.3760/cma.j.issn.0366-6999.2009.12.011
中图分类号:
R5 [内科学];
学科分类号:
1002 ;
100201 ;
摘要:
Background Homoharringtonine (HHT) is effective in treating late stage chronic myelogenous leukaemia (CIVIL), but little is known about long term maintenance during complete cytogenetic response. Long term efficacy and toxicity profiles of low dose HHT were evaluated in this study. Methods One hundred and six patients with CIVIL received 1.5 mg/m(2) of HHT alone by continuous daily infusion for seven to nine days every four weeks. Of 79 patients in the control group, 31 were treated with interferon alpha (IFN-alpha) and 48 with hydroxycarbamide. For 17 patients who failed to achieve cytogenetic response within 12 months' treatment of IFN-alpha, HHT was administered. Quantitative RT-PCR was used to detect the BCR-ABL mRNA expression in 36 Philadelphia positive CML patients enrolled after 2007. Haematological and cytogenetic responses were evaluated in all patients at the 12th month of follow-up. Long term efficacy was assessed in a follow-up with a median time of 54 months (12 months-98 months). Results After 12 months of therapy, cytogenetic response rate of the HHT IFN-a and hydroxycarbamide groups were 39/106, 14/31 and 3/48, and corresponding molecular cytogenetic response rates 6/18, 3/8 and 0. Of the 17 patients who received HHT as salvage treatment, 6 achieved cytogenetic response (3 major). At the 48 months' follow-up, cytogenetic response was maintained in 32/39 patients treated with HHT Patients who had cytogenetic response in HHT group or treated with IFN-a also showed longer median chronic durations, which were 45 months (12 months-98 months) and 49 months (12 months-92 months) respectively, indicating a longer survival time. Conclusions Low dose HHT alone showed considerable short term and long term efficacy in the treatment of late stage CIVIL. It may also be a good choice for patients who have failed imatinib, IFN-a treatment or haematopoietic stem cell transplantation or cannot afford these treatments. Chin Med J 2009;122(12):1413-1417
机构:
Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02114 USAHarvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA
机构:
Univ Washington, Fred Hutchinson Canc Res Ctr, Sch Med, Seattle, WA 98195 USAUniv Washington, Fred Hutchinson Canc Res Ctr, Sch Med, Seattle, WA 98195 USA
Radich, Jerald P.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK,
2016,
14
(5.5):
: 669
-
671
机构:
Nationwide Childrens Hosp, Div Hematol Oncol BMT, Columbus, OH USA
Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USAUniv Illinois, Dept Pediat, Div Pediat Hematol & Oncol, Chicago, IL 60612 USA
Setty, Bhuvana A.
Hayani, Karen C.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Illinois, Dept Pediat, Div Pediat Infect Dis, Chicago, IL 60612 USAUniv Illinois, Dept Pediat, Div Pediat Hematol & Oncol, Chicago, IL 60612 USA
Hayani, Karen C.
Sharon, Bruce I.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Illinois, Dept Pediat, Div Pediat Hematol & Oncol, Chicago, IL 60612 USAUniv Illinois, Dept Pediat, Div Pediat Hematol & Oncol, Chicago, IL 60612 USA
Sharon, Bruce I.
Schmidt, Mary Lou
论文数: 0引用数: 0
h-index: 0
机构:
Univ Illinois, Dept Pediat, Div Pediat Hematol & Oncol, Chicago, IL 60612 USAUniv Illinois, Dept Pediat, Div Pediat Hematol & Oncol, Chicago, IL 60612 USA